Bortezomib Injection ( DrugBank: Bortezomib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 64 | Thrombotic thrombocytopenic purpura | 1 |
64. Thrombotic thrombocytopenic purpura
Clinical trials : 86 / Drugs : 81 - (DrugBank : 20) / Drug target genes : 16 - Drug target pathways : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05135442 (ClinicalTrials.gov) | December 1, 2021 | 6/11/2021 | Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP | The Efficacy and Safety of Bortezomib as First-line Treatment for Acquired Thrombotic Thrombocytopenic Purpura | Thrombotic Thrombocytopenic Purpura, Acquired | Drug: Bortezomib Injection | Peking Union Medical College Hospital | NULL | Not yet recruiting | 18 Years | 80 Years | All | 30 | Phase 4 | China |